Meta AnalysisID 4517
川芎嗪治疗特发性肺纤维化的临床疗效与安全性Meta分析
CRD42020193626
This study collected randomized controlled trials (RCT) of ligustrazine in the treatment of IPF. The effectiveness and safety of ligustrazine in the treatment of IPF were evaluated objectively by systematic evaluation me
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4517
- Evidence Id
- 13075
- Core Evidence Id
- 13075
- Source Meta Analysis Id
- 4486
- Herb2 Meta Analysis Id
- HBMA004486
- Crd Id
- CRD42020193626
- Title
- Meta-analysis of clinical efficacy and safety of ligustrazine in the treatment of idiopathic pulmonary fibrosis
- Review Question
- This study collected randomized controlled trials (RCT) of ligustrazine in the treatment of IPF. The effectiveness and safety of ligustrazine in the treatment of IPF were evaluated objectively by systematic evaluation method to provided evidence-based medical basis for its clinical application.
- Study Type Included
- Randomized controlled trials (RCTs) will be included.
- Condition Being Studied
- Idiopathic pulmonary fibrosis(IPF) is a different type of chronic progressive pulmonary interstitial inflammation and fibrosis with unknown etiology. Its histopathological process includes a series of processes, such as internal injury of epithelial cells, inflammatory exudation, myofibroblast formation, fibroblast aggregation and fibrosis scar formation, which lead to irreversible pathological changes of lung tissue structure. The thoracic HRCT will show general interstitial pneumonia. The main clinical symptoms are dry cough without sputum or only a small amount of foam sputum, chronic progressive dyspnea, and general fatigue. The failure of normal blood gas exchange in its lungs eventually leads to respiratory failure and death, which is the common outcome of a variety of lung diseases. In the past 20 years, its incidence has increased, with a median survival period of 3-5 years and a 5-year survival rate of 20-40%. The 2015 Guidelines for the Diagnosis and Treatment of Idiopathic Interstitial Pneumonia pointed out that there was no evidence to prove which medicine can effectively treat IPF except lung transplantation. The guidelines recommended pifenidone and nidanib which are not widely used in China due to the large side effects and the high price .
- Participant
- Inclusion criteria：Randomized controlled trial (RCT) of ligustrazine in the treatment of IPF in Chinese or English, whether or not blind and allocation concealment were used. It conforms to the authoritative standards established by the Society of Respiratory Diseases of the Chinese Medical Association in 2002 or the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society in China and abroad. Its gender, age, race and nationality are not limited, excluding serious diseases associated with other systems. Exclusion Criteria：non-randomized controlled trials, reviews, case reports, experimental studies, expert experience, incomplete information and repeated publication were excluded. For multiple publications of the same study, only one with the largest sample size and the most complete information was retained.
- Animal
- Human Disease Modelled
- Intervention
- The experimental group: Ligustrazine treatment or Ligustrazine treatment given on the basis of the control group are not limited with dosage, dosage form, route and method of administration .
- Comparator Control
- The control group: Drugs (hormones, N-acetylcysteine, cyclophosphamide, azathioprine, etc.) and combined with the same routine treatment. The dosage and course of treatment are not limited. Routine treatment refers to oxygen therapy, lung function training, antibiotic therapy and other measures.
- Main Outcome
- A:Total clinical effective rate: according to the clinical physiological x-ray (CRP) comprehensive scoring method developed by Watters et al. Measures of effect Odds ratios.
- Outcome Measure
- Additional Outcome
- B:Pulmonary function; C:Arterial blood gas analysis; D:Adverse reactions. Measures of effect Odds ratios, the mean difference (MD), weighted mean differences (WMD) .
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Humans; Idiopathic Pulmonary Fibrosis; Pyrazines; Treatment Outcome
- Contact
- Xiaozheng Wu [email protected]
- Organisational Affiliation
- Guizhou University of traditional Chinese Medicine http://www.gzy.edu.cn/
- Funding Source
- This work was supported by the Doctor start-up fund of Guizhou University of traditional Chinese Medicine in china(grant no:3043-043190021), the National Natural Science Foundation of China (nos. 81760841, 81874376), the Research Projects of Science and Technology of Science and Technology Program in Guizhou Province (Qiankehe [2017]1401), and the Project of Education Department of Guizhou Province (K[2017]041)
- Other Selection Criteria
- Final Publication
- Xiaozheng Wu, Wen Li, Zhenliang Luo, Yunzhi Chen, Meta-Analysis of Clinical Efficacy and Safety of Ligustrazine in the Treatment of Idiopathic Pulmonary Fibrosis, Evidence-Based Complementary and Alternative Medicine, vol. 2020, Article ID 2416132, 11 pages, 2020. https://doi.org/10.1155/2020/2416132 https://doi.org/10.1155/2020/2416132
- Same Topic Review
- Published Protocol
- Review Type
- Language
- Chinese-Trad, English
- Country
- China
- Review Stage
- Review Completed published
- First Submission Date
- 2020-06-23
- Registration Date
- 2020-07-23
- Anticipated Start Date
- 2019-08-01
- Anticipated Completion Date
- 2020-07-31
- Title Cn
- 川芎嗪治疗特发性肺纤维化的临床疗效与安全性Meta分析
- Title En
- Meta-analysis of clinical efficacy and safety of ligustrazine in the treatment of idiopathic pulmonary fibrosis
- Bilingual Status
- complete